HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating on Zymeworks (NASDAQ:ZYME) and maintained a $12 price target.
November 01, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Zymeworks and maintained a $12 price target, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $12 price target by HC Wainwright & Co. suggests that the analyst does not foresee significant changes in Zymeworks' stock price in the short term. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100